Effect of the tyrosine kinase inhibitor lapatinib on CUB-domain containing protein (CDCP1)-mediated breast cancer cell survival and migration

Biochemical and Biophysical Research Communications

Volumn 414, Issue 1, 2011, Pages 226-232

  Seidel, Jeanette ^a   Kunc, Klaudia ^a   Possinger, Kurt ^a   Jehn, Christian ^a   Lüftner, Diana ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Anchorage independency; CDCP1; Lapatinib; Tumor cell migration; Tyrosine kinase inhibitor

Indexed keywords

CUB DOMAIN CONTAINING PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TUMOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; HUMANS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; QUINAZOLINES; RECEPTOR, ERBB-2; THYMIDINE KINASE;

EID: 80054073804     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.062     Document Type: Article

References (19)

1. Alvares S.M., Dunn C.A., Brown T.A., Wayner E.E., Carter W.G. The role of membrane microdomains in transmembrane signaling through the epithelial glycoprotein Gp140/CDCP1. Biochim. Biophys. Acta 2008, 1780:486-496.
2. Hooper J.D., Zijlstra A., Aimes R.T., Liang H., Claassen G.F., Tarin D., Testa J.E., Quigley J.P. Subtractive immunization using highly metastatic human tumor cells identifies SIMA135/CDCP1, a 135kDa cell surface phosphorylated glycoprotein antigen. Oncogene 2003, 22:1783-1794.
3. Siva A.C., Wild M.A., Kirkland R.E., Nolan M.J., Lin B., Maruyama T., Yantiri-Wernimont F., Frederickson S., Bowdish K.S., Xin H. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res. 2008, 68:3759-3766.
4. Buhring H.J., Kuci S., Conze T., Rathke G., Bartolovic K., Grunebach F., Scherl-Mostageer M., Brummendorf T.H., Schweifer N., Lammers R. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells 2004, 22:334-343.
5. Conze T., Lammers R., Kuci S., Scherl-Mostageer M., Schweifer N., Kanz L., Buhring H.J. CDCP1 is a novel marker for hematopoietic stem cells. Ann. N.Y. Acad. Sci. 2003, 996:222-226.
6. Ikeda J., Oda T., Inoue M., Uekita T., Sakai R., Okumura M., Aozasa K., Morii E. Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. Cancer Sci. 2009, 100:429-433.
7. Mamat S., Ikeda J., Enomoto T., Ueda Y., Rahadiani N., Tian T., Wang Y., Qiu Y., Kimura T., Aozasa K., Morii E. Prognostic significance of CUB domain containing protein expression in endometrioid adenocarcinoma. Oncol. Rep. 2010, 23:1221-1227.
8. Miyazawa Y., Uekita T., Hiraoka N., Fujii S., Kosuge T., Kanai Y., Nojima Y., Sakai R. CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. Cancer Res. 2010, 70:5136-5146.
9. Perry S.E., Robinson P., Melcher A., Quirke P., Buhring H.J., Cook G.P., Blair G.E. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. 2007, 581:1137-1142.
10. Bhatt A.S., Erdjument-Bromage H., Tempst P., Craik C.S., Moasser M.M. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene 2005, 24:5333-5343.
11. Spassov D.S., Baehner F.L., Wong C.H., McDonough S., Moasser M.M. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am. J. Pathol. 2009, 174:1756-1765.
12. Wong C.H., Baehner F.L., Spassov D.S., Ahuja D., Wang D., Hann B., Blair J., Shokat K., Welm A.L., Moasser M.M. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin. Cancer Res. 2009, 15:2311-2322.
13. Brown T.A., Yang T.M., Zaitsevskaia T., Xia Y., Dunn C.A., Sigle R.O., Knudsen B., Carter W.G. Adhesion or plasmin regulates tyrosine phosphorylation of a novel membrane glycoprotein p80/gp140/CUB domain-containing protein 1 in epithelia. J. Biol. Chem. 2004, 279:14772-14783.
14. Benes C.H., Wu N., Elia A.E., Dharia T., Cantley L.C., Soltoff S.P. The C2 domain of PKCdelta is a phosphotyrosine binding domain. Cell 2005, 121:271-280.
15. Uekita T., Jia L., Narisawa-Saito M., Yokota J., Kiyono T., Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol. Cell. Biol. 2007, 27:7649-7660.
16. He Y., Wortmann A., Burke L.J., Reid J.C., Adams M.N., Abdul-Jabbar I., Quigley J.P., Leduc R., Kirchhofer D., Hooper J.D. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J. Biol. Chem. 2010, 285:26162-26173.
17. Albanell J., Gascon P. Small molecules with EGFR-TK inhibitor activity. Curr. Drug Targets 2005, 6:259-274.
18. Costa S.D., Jackisch C., Thomssen C. Future roles of lapatinib in ErbB2-positive breast cancer: adjuvant and neoadjuvant trials. Breast Care (Basel) 2010, 5:22-24.
19. Johnston S.R., Leary A. Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer. Drugs Today (Barc.) 2006, 42:441-453.